BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37626304)

  • 1. VSIG2 promotes malignant progression of pancreatic ductal adenocarcinoma by enhancing LAMTOR2-mediated mTOR activation.
    Xu J; Quan G; Huang W; Jiang J
    Cell Commun Signal; 2023 Aug; 21(1):223. PubMed ID: 37626304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The long non-coding RNA DKFZp434J0226 regulates the alternative splicing process through phosphorylation of SF3B6 in PDAC.
    Li J; Tong H; Li D; Jiang Q; Zhang Y; Tang W; Jin D; Chen S; Qin X; Zhang S; Xue R
    Mol Med; 2021 Aug; 27(1):95. PubMed ID: 34470609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
    Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
    J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2.
    Li J; Yang R; Dong Y; Chen M; Wang Y; Wang G
    J Exp Clin Cancer Res; 2019 Jan; 38(1):38. PubMed ID: 30691517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism.
    Zhu H; Xiao Y; Guo H; Guo Y; Huang Y; Shan Y; Bai Y; Lin X; Lu H
    Aging (Albany NY); 2021 Dec; 13(23):25089-25105. PubMed ID: 34863080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4.
    Fu Y; Liu X; Chen Q; Liu T; Lu C; Yu J; Miao Y; Wei J
    J Exp Clin Cancer Res; 2018 Jul; 37(1):130. PubMed ID: 29970191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis.
    Guo X; Zhou Q; Su D; Luo Y; Fu Z; Huang L; Li Z; Jiang D; Kong Y; Li Z; Chen R; Chen C
    Mol Cancer; 2020 May; 19(1):83. PubMed ID: 32375768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRG-1 promotes pancreatic cancer growth and metastasis via modulation of the EGFR/p38 signaling.
    Xie ZB; Zhang YF; Jin C; Mao YS; Fu DL
    J Exp Clin Cancer Res; 2019 Feb; 38(1):75. PubMed ID: 30760292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of laminin-5 gamma-2 promotes tumorigenesis of pancreatic ductal adenocarcinoma through EGFR/ERK1/2/AKT/mTOR cascade.
    Kirtonia A; Pandey AK; Ramachandran B; Mishra DP; Dawson DW; Sethi G; Ganesan TS; Koeffler HP; Garg M
    Cell Mol Life Sci; 2022 Jun; 79(7):362. PubMed ID: 35699794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathway.
    Liu X; Tan X; Liu P; Wu Y; Qian S; Zhang X
    Oncol Res; 2018 Aug; 26(7):1123-1131. PubMed ID: 29386088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of amplified in breast cancer 1 contributes to pancreatic ductal adenocarcinoma progression and vulnerability to blockage of hedgehog activation.
    Li L; Bao J; Wang H; Lei JH; Peng C; Zeng J; Hao W; Zhang X; Xu X; Yu C; Deng CX; Chen Q
    Theranostics; 2021; 11(4):1672-1689. PubMed ID: 33408774
    [No Abstract]   [Full Text] [Related]  

  • 13. Downregulated expression of IL‑28RA is involved in the pathogenesis of pancreatic ductal adenocarcinoma.
    Liu L; Qi Y; Huang D; Xu Y; Li M; Hong Z; Gu Y; Jia B; Luo X; Zhang S; Zhang S
    Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34195850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FUS-induced circRHOBTB3 facilitates cell proliferation via miR-600/NACC1 mediated autophagy response in pancreatic ductal adenocarcinoma.
    Yang T; Shen P; Chen Q; Wu P; Yuan H; Ge W; Meng L; Huang X; Fu Y; Zhang Y; Hu W; Miao Y; Lu Z; Jiang K
    J Exp Clin Cancer Res; 2021 Aug; 40(1):261. PubMed ID: 34416910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ETV4 promotes pancreatic ductal adenocarcinoma metastasis through activation of the CXCL13/CXCR5 signaling axis.
    Gao X; Jiang M; Chu Y; Han Y; Jin Y; Zhang W; Wang W; Yang S; Li W; Fan A; Cao J; Wang J; Liu H; Fu X; Chen D; Nie Y; Fan D
    Cancer Lett; 2022 Jan; 524():42-56. PubMed ID: 34582976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. lncRNA
    Li N; Yang G; Luo L; Ling L; Wang X; Shi L; Lan J; Jia X; Zhang Q; Long Z; Liu J; Hu W; He Z; Liu H; Liu W; Zheng G
    Clin Cancer Res; 2020 Apr; 26(7):1736-1748. PubMed ID: 31831555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIF11 manipulates SREBP2-dependent mevalonate cross talk to promote tumor progression in pancreatic ductal adenocarcinoma.
    Gu X; Zhu Q; Tian G; Song W; Wang T; Wang A; Chen X; Qin S
    Cancer Med; 2022 Sep; 11(17):3282-3295. PubMed ID: 35619540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MTA2-mediated inhibition of PTEN leads to pancreatic ductal adenocarcinoma carcinogenicity.
    Si W; Liu X; Wei R; Zhang Y; Zhao Y; Cui L; Hong T
    Cell Death Dis; 2019 Feb; 10(3):206. PubMed ID: 30814496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-neuroglia interaction promotes pancreatic cancer metastasis.
    Su D; Guo X; Huang L; Ye H; Li Z; Lin L; Chen R; Zhou Q
    Theranostics; 2020; 10(11):5029-5047. PubMed ID: 32308766
    [No Abstract]   [Full Text] [Related]  

  • 20. Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism.
    Zhang JJ; Zhu Y; Xie KL; Peng YP; Tao JQ; Tang J; Li Z; Xu ZK; Dai CC; Qian ZY; Jiang KR; Wu JL; Gao WT; Du Q; Miao Y
    Mol Cancer; 2014 May; 13():130. PubMed ID: 24884523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.